600557 Stock Overview
Jiangsu Kanion Pharmaceutical Co.,Ltd. investiga y desarrolla, produce y vende medicamentos chinos.
Snowflake Score | |
---|---|
Valuation | 6/6 |
Future Growth | 1/6 |
Past Performance | 5/6 |
Financial Health | 6/6 |
Dividends | 4/6 |
Rewards
Risk Analysis
Jiangsu Kanion Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥20.97 |
52 Week High | CN¥32.25 |
52 Week Low | CN¥13.36 |
Beta | 0.34 |
1 Month Change | 11.60% |
3 Month Change | 1.55% |
1 Year Change | -33.43% |
3 Year Change | 102.41% |
5 Year Change | 46.64% |
Change since IPO | -2.84% |
Recent News & Updates
Recent updates
Shareholder Returns
600557 | CN Pharmaceuticals | CN Market | |
---|---|---|---|
7D | 1.1% | 0.7% | 0.9% |
1Y | -33.4% | -14.7% | -16.5% |
Rentabilidad frente al sector: 600557 obtuvo unos resultados inferiores a los del sector CN Pharmaceuticals , que el año pasado arrojó un rendimiento del -18.3%.
Rentabilidad vs. Mercado: 600557 obtuvo unos resultados inferiores a los del mercado CN, que fue del -22% el año pasado.
Price Volatility
600557 volatility | |
---|---|
600557 Average Weekly Movement | 8.6% |
Pharmaceuticals Industry Average Movement | 7.2% |
Market Average Movement | 8.3% |
10% most volatile stocks in CN Market | 11.6% |
10% least volatile stocks in CN Market | 5.2% |
Precio estable de las acciones: 600557ha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de 600557 (7%) se ha mantenido estable durante el año pasado.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1975 | 5,443 | Yong Chun Yang | https://www.kanion.com |
Jiangsu Kanion Pharmaceutical Co.,Ltd. investiga y desarrolla, produce y vende medicamentos chinos. La empresa ofrece medicamentos en los campos de antiinfecciones, ortopedia, ginecología, cardiovascular y cerebrovascular, tónicos y otros.
Jiangsu Kanion Pharmaceutical Co.,Ltd. Fundamentals Summary
600557 fundamental statistics | |
---|---|
Market cap | CN¥12.24b |
Earnings (TTM) | CN¥536.73m |
Revenue (TTM) | CN¥4.87b |
22.8x
P/E Ratio2.5x
P/S RatioIs 600557 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
600557 income statement (TTM) | |
---|---|
Revenue | CN¥4.87b |
Cost of Revenue | CN¥1.26b |
Gross Profit | CN¥3.61b |
Other Expenses | CN¥3.08b |
Earnings | CN¥536.73m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 13, 2024
Earnings per share (EPS) | 0.92 |
Gross Margin | 74.21% |
Net Profit Margin | 11.03% |
Debt/Equity Ratio | 0.04% |
How did 600557 perform over the long term?
See historical performance and comparison